Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia

References

• Addington D, Addington J, Maticka-Tyndale E. 1993. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry. 163(S22):39–44.
   Web of Science ®Google Scholar
• Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. 2015. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 182:106–114.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): APA.
   Google Scholar
• Ang MS, Rekhi G, Lee J. 2020. Vocational profile and correlates of employment in people with schizophrenia: the role of avolition. Front Psychiatry. 11:856.
   PubMed Web of Science ®Google Scholar
• Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, Prieto D, Palomo T. 2006. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry. 163(3):488–493.
   PubMed Web of Science ®Google Scholar
• Auquier P, Simeoni MC, Sapin C, Reine G, Aghababian V, Cramer J, Lançon C. 2003. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr Res. 63(1–2):137–149.
   PubMed Web of Science ®Google Scholar
• Bahorik AL, Greeno CG, Cochran G, Cornelius JR, Eack SM. 2017. Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia. Psychiatry Res. 253:391–397.
   PubMed Web of Science ®Google Scholar
• Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry. 154:672–676.
   PubMed Web of Science ®Google Scholar
• Bender R, Lange S. 2001. Adjusting for multiple testing—when and how? J Clin Epidemiol. 54(4):343–349.
   PubMed Web of Science ®Google Scholar
• Bodén R, Bengtsson J, Thörnblom E, Struckmann W, Persson J. 2021. Dorsomedial prefrontal theta burst stimulation to treat anhedonia, avolition, and blunted affect in schizophrenia or depression – a randomized controlled trial. J Affect Disord. 290:308–315.
   PubMed Web of Science ®Google Scholar
• Boyer L, Simeoni M-C, Loundou A, D'Amato T, Reine G, Lancon C, Auquier P. 2010. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res. 121(1–3):241–250.
   PubMed Web of Science ®Google Scholar
• Bradley ER, Brustkern J, De Coster L, van den Bos W, McClure SM, Seitz A, Woolley JD. 2020. Victory is its own reward: oxytocin increases costly competitive behavior in schizophrenia. Psychol Med. 50(4):674–682.
   PubMed Web of Science ®Google Scholar
• Brandt SJ, Oral HY, Arellano-Bravo C, Plawecki MH, Hummer TA, Francis MM. 2021. Repetitive transcranial magnetic stimulation as a therapeutic and probe in schizophrenia: examining the role of neuroimaging and future directions. Neurother J Am Soc Exp Neurother. 18(2):827–844.
   Google Scholar
• Bromberg-Martin ES, Matsumoto M, Hikosaka O. 2010. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 68(5):815–834.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA. 2015. Rasagiline in the treatment of the persistent negative symptoms of schizophrenia. Schizophr Bull. 41(4):900–908.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28(2):193–213.
   PubMed Web of Science ®Google Scholar
• Cather C, Pachas GN, Cieslak KM, Evins AE. 2017. Achieving smoking cessation in individuals with schizophrenia: special considerations. CNS Drugs. 31(6):471–481.
   PubMed Web of Science ®Google Scholar
• DeAtley T, Denlinger-Apte RL, Cioe PA, Colby SM, Cassidy RN, Clark MA, Donny EC, Tidey JW. 2020. Biopsychosocial mechanisms associated with tobacco use in smokers with and without serious mental illness. Prev Med. 140:106190.
   PubMed Web of Science ®Google Scholar
• Etchecopar-Etchart D, Korchia T, Loundou A, Llorca P-M, Auquier P, Lançon C, et al. 2021. Comorbid major depressive disorder in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 47(2):298–308.
   PubMed Web of Science ®Google Scholar
• Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, Le NA, Feinberg R, Tansey MG, Miller AH. 2018. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry. 25:1301–311.
   PubMed Web of Science ®Google Scholar
• Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G. 2015. Antipsychotics and amotivation. Neuropsychopharmacology. 40(6):1539–1548.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. 2002. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
   Google Scholar
• Fond G, Boyer L, Berna F, Godin O, Bulzacka E, Andrianarisoa M, Brunel L, Aouizerate B, Capdevielle D, Chereau I, et al. 2018. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. Br J Psychiatry. 213(2):464–470.
   PubMed Web of Science ®Google Scholar
• Fond G, Boyer L, Boucekine M, Aden LA, Schürhoff F, Tessier A, Andrianarisoa M, Berna F, Brunel L, Capdevielle D, et al. 2017. Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. Schizophr Res. 182:84–89.
   PubMed Web of Science ®Google Scholar
• Fond G, Faugere M, Richieri R, Cermolacce M, Korchia T, Micoulaud-Franchi JA, Sunhary de Verville PL, Boyer L, Lançon C. 2021. Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission. J Affect Disord. 280:267–271.
   PubMed Web of Science ®Google Scholar
• Fond G, Godin O, Schürhoff F, Berna F, André M, Aouizerate B, Capdevielle D, Chereau I, D' Amato T, Dubertret C, et al. 2020. Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort. Prog Neuropsychopharmacol Biol Psychiatry. 101:109927.
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. 2010. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 36(2):359–369.
   PubMed Web of Science ®Google Scholar
• Fulford D, Piskulic D, Addington J, Kane JM, Schooler NR, Mueser KT. 2018. Prospective relationships between motivation and functioning in recovery after a first episode of schizophrenia. Schizophr Bull. 44(2):369–377.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Bucci P, Mucci A, Kirkpatrick B, Pini S, Rossi A, Vita A, Maj M. 2013. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 147(1):157–162.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Buchanan RW, Arango C. 2018. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 5(8):664–677.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, et al. 2014. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry Off. World Psychiatry. 13(3):275–287.
   PubMed Web of Science ®Google Scholar
• Godin O, Leboyer M, Gaman A, Aouizerate B, Berna F, Brunel L, Capdevielle D, Chereau I, Dorey JM, Dubertret C, et al. 2015. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort. Schizophr Res. 168(1–2):388–294.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH. 2020. Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psychiatry. 11:46.
   PubMed Web of Science ®Google Scholar
• Gupta T, Cowan HR, Strauss GP, Walker EF, Mittal VA. 2021. Deconstructing negative symptoms in individuals at clinical high-risk for psychosis: evidence for volitional and diminished emotionality subgroups that predict clinical presentation and functional outcome. Schizophr Bull. 47(1):54–63.
   PubMed Web of Science ®Google Scholar
• Hager OM, Kirschner M, Bischof M, Hartmann-Riemer MN, Kluge A, Seifritz E, Tobler PN, Kaiser S. 2015. Reward-dependent modulation of working memory is associated with negative symptoms in schizophrenia. Schizophr Res. 168(1-2):238–244.
   PubMed Web of Science ®Google Scholar
• Hagi K, Nosaka T, Dickinson D, Lindenmayer JP, Lee J, Friedman J, Boyer L, Han M, Abdul-Rashid NA, Correll CU, et al. 2021. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 78(5):510.
   PubMed Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodríguez MJ, Rele R, Orta J, Kharbeng A, et al. 2003. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 107:16–23.
   Google Scholar
• Harvey PD, Saoud JB, Luthringer R, Moroz S, Blazhevych Y, Stefanescu C, Davidson M. 2020. Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: reduced emotional experience and reduced emotional expression. Schizophr Res. 215:352–356.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller H-J, 2015. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 16(3):142–170.
   PubMed Web of Science ®Google Scholar
• Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. 1991. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 86(9):1119–1127.
   PubMedGoogle Scholar
• Hunt GE, Siegfried N, Morley K, Brooke-Sumner C, Cleary M. 2019. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 12:CD001088.
   PubMedGoogle Scholar
• Kasparek SW, Jenness JL, McLaughlin KA. 2020. Reward processing modulates the association between trauma exposure and externalizing psychopathology. Clin Psychol Sci. 8(6):989–1006.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, et al. 2015. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 35(4):374–381.
   PubMed Web of Science ®Google Scholar
• Kenney SR, Lac A, Labrie JW, Hummer JF, Pham A. 2013. Mental health, sleep quality, drinking motives, and alcohol-related consequences: a path-analytic model. J Stud Alcohol Drugs. 74(6):841–851.
   PubMed Web of Science ®Google Scholar
• Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D. 2006. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull. 32(2):274–278.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B. 2014. Recognizing primary vs secondary negative symptoms and apathy vs expression domains. J Clin Psychiatry. 75(4):e09.
   PubMedGoogle Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. 2006. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 32(2):214–219.
   PubMed Web of Science ®Google Scholar
• Krynicki CR, Dazzan P, Pariante CM, Barnes NM, Vincent RC, Roberts A, Giordano A, Watson A, Suckling J, Barnes TRE, et al. 2021. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immun. 91:498–504.
   PubMed Web of Science ®Google Scholar
• Krynicki CR, Upthegrove R, Deakin JFW, Barnes TRE. 2018. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand. 137(5):380–390.
   PubMed Web of Science ®Google Scholar
• Laksmidewi AAAP, Soejitno A. 2021. Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors. J Neural Transm. 128(5):615–630.
   PubMed Web of Science ®Google Scholar
• Liverant GI, Arditte Hall KA, Wieman ST, Pineles SL, Pizzagalli DA. 2021. Associations between insomnia and reward learning in clinical depression. Psychol Med. 1–10. doi:10.1017/S003329172100026X
   PubMed Web of Science ®Google Scholar
• Luther L, Fischer MW, Johnson-Kwochka AV, Minor KS, Holden R, Lapish CL, McCormick B, Salyers MP. 2020. Mobile enhancement of motivation in schizophrenia: a pilot randomized controlled trial of a personalized text message intervention for motivation deficits. J Consult Clin Psychol. 88(10):923–936.
   PubMed Web of Science ®Google Scholar
• Mas S, Gassó P, Fernández de Bobadilla R, Arnaiz JA, Bernardo M, Lafuente A. 2013. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum Psychopharmacol. 28(6):586–593.
   PubMed Web of Science ®Google Scholar
• McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. 2016. Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull. 42(1):96–124.
   PubMed Web of Science ®Google Scholar
• Meyer N, Faulkner SM, McCutcheon RA, Pillinger T, Dijk D-J, MacCabe JH. 2020. Sleep and circadian rhythm disturbance in remitted schizophrenia and bipolar disorder: a systematic review and meta-analysis. Schizophr Bull. 46(5):1126–1143.
   PubMed Web of Science ®Google Scholar
• Misdrahi D, Tessier A, Daubigney A, Meissner WG, Schurhoff F, Boyer L, Godin O, Bulzacka E, Aouizerate B, Andrianarisoa M, et al. 2019. Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort. J Clin Psychiatry. 80(1):18m12246.
   PubMed Web of Science ®Google Scholar
• Misdrahi D, Tessier A, Swendsen J, Berna F, Brunel L, Capdevielle D, Chereau I, Danion J-M, De Pradier M, Dorey J-M, et al. 2016. Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset. J Clin Psychiatry. 77(9):e1130–e1136.
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. 2000. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 101(4):323–329.
   PubMed Web of Science ®Google Scholar
• Mucci A, Galderisi S, Gibertoni D, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Bellomo A, Biondi M, et al. 2021. Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian Network for Research on Psychoses. JAMA Psychiatry. 78(5):550–559.
   PubMed Web of Science ®Google Scholar
• Mulhern B, Mukuria C, Barkham M, Knapp M, Byford S, Soeteman D, Brazier J. 2014. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry. 205(3):236–243.
   PubMed Web of Science ®Google Scholar
• NICE Clinical Guideline. 2014. Psychosis and schizophrenia in adults: prevention and management. 39. London: National Institute for Health and Care Excellence (NICE).
   Google Scholar
• Perry BI, Burgess S, Jones HJ, Zammit S, Upthegrove R, Mason AM, Day FR, Langenberg C, Wareham NJ, Jones PB, et al. 2021. The potential shared role of inflammation in insulin resistance and schizophrenia: a bidirectional two-sample Mendelian randomization study. PLoS Med. 18(3):e1003455.
   PubMed Web of Science ®Google Scholar
• Prikryl R, Ustohal L, Prikrylova Kucerova H, Kasparek T, Venclikova S, Vrzalova M, Ceskova E. 2013. A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: a double-blind trial. Schizophr Res. 149(1–3):167–173.
   PubMed Web of Science ®Google Scholar
• Rivière F, Widad FZ, Speyer E, Erpelding M-L, Escalon H, Vuillemin A. 2018. Reliability and validity of the French version of the global physical activity questionnaire. J Sport Health Sci. 7(3):339–345.
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling W, Leucht S. 2006. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006:CD005581.
   Google Scholar
• Russell K, Rasmussen S, Hunter SC. 2018. Insomnia and nightmares as markers of risk for suicidal ideation in young people: investigating the role of defeat and entrapment. J Clin Sleep Med. 14(5):775–784.
   PubMed Web of Science ®Google Scholar
• Salamone JD, Yohn SE, López-Cruz L, San Miguel N, Correa M. 2016. Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology. Brain. 139(Pt 5):1325–1347.
   PubMedGoogle Scholar
• Schermitzler B, Miley K, Vinogradov S, Ramsay IS. 2021. Smoking is related to reduced motivation, but not global cognition, in the first two years of treatment for first episode psychosis. J Clin Med. 10:1619.
   PubMed Web of Science ®Google Scholar
• Schlosser DA, Campellone TR, Truong B, Etter K, Vergani S, Komaiko K, Vinogradov S. 2018. Efficacy of PRIME, a mobile app intervention designed to improve motivation in young people with schizophrenia. Schizophr Bull. 44(5):1010–1020.
   PubMed Web of Science ®Google Scholar
• Schürhoff F, Fond G, Berna F, Bulzacka E, Godin O, Boyer L, et al. 2018. The 10-year findings from the FondaMental Academic Center of Expertise for Schizophrenia (FACE-SZ): review and recommendations for clinical practice. L’Encephale.
   Google Scholar
• Schürhoff F, Fond G, Berna F, Bulzacka E, Vilain J, Capdevielle D, Misdrahi D, Leboyer M, Llorca P-M. 2015. A national network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap. Eur Psychiatr. 30(6):728–735.
   PubMed Web of Science ®Google Scholar
• Shimada T, Ito S, Makabe A, Yamanushi A, Takenaka A, Kobayashi M. 2019. Aerobic exercise and cognitive functioning in schizophrenia: a pilot randomized controlled trial. Psychiatry Res. 282:112638.
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:11–9.
   Google Scholar
• Smith SM, O'Keane V, Murray R. 2002. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 181:49–55.
   PubMed Web of Science ®Google Scholar
• Startup M, Jackson MC, Bendix S. 2002. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol. 41(Pt 4):417–422.
   PubMedGoogle Scholar
• Strauss GP, Bartolomeo LA, Harvey PD. 2021. Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr. 7(1):16.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Esfahlani FZ, Kirkpatrick B, Allen DN, Gold JM, Visser KF, Sayama H. 2019. Network analysis reveals which negative symptom domains are most central in schizophrenia vs bipolar disorder. Schizophr Bull. 45(6):1319–1330.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Koyanagi A, Schuch F, Firth J, Rosenbaum S, Gaughran F. 2017. Physical activity levels and psychosis: a mediation analysis of factors influencing physical activity target achievement among 204 186 people across 46 low- and middle-income countries. Schizophr Bull. 43:536–545.
   PubMed Web of Science ®Google Scholar
• Sunhary de Verville PL, Etchecopar-Etchart D, Richieri R, Godin O, Schürhoff F, Berna F, Aouizerate B, Capdevielle D, Chereau I, D'Amato T, et al. 2021. Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. Prog Neuropsychopharmacol Biol Psychiatry. 110:110275.
   PubMed Web of Science ®Google Scholar
• Tsang HWH, Leung AY, Chung RCK, Bell M, Cheung W-M. 2010. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry. 44:495–504.
   PubMed Web of Science ®Google Scholar
• Uchino T, Nemoto T, Kojima A, Takubo Y, Kotsuji Y, Yamaguchi E, Yamaguchi T, Katagiri N, Tsujino N, Tanaka K, et al. 2021. Effects of motivation domains on social functioning in schizophrenia with consideration of the factor structure and confounding influences. J Psychiatr Res. 133:106–112.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, De Hert M, Stubbs B, Ward PB, Rosenbaum S, Soundy A, Probst M. 2015. Negative symptoms are associated with lower autonomous motivation towards physical activity in people with schizophrenia. Compr Psychiatry. 56:128–132.
   PubMed Web of Science ®Google Scholar
• Weye N, Santomauro DF, Agerbo E, Christensen MK, Iburg KM, Momen NC, Mortensen PB, Pedersen CB, Whiteford HA, McGrath JJ, et al. 2021. Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark. Lancet Psychiatry. 8(4):310–319.
   PubMed Web of Science ®Google Scholar
• Yang X, Huang J, Harrision P, Roser ME, Tian K, Wang D, Liu G. 2021. Motivational differences in unipolar and bipolar depression, manic bipolar, acute and stable phase schizophrenia. J Affect Disord. 283:254–261.
   PubMed Web of Science ®Google Scholar